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Convalescent plasma in patients admitted to hospital with 




Background Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. 
We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with 
COVID-19.
Methods This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy 
[RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is 
underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to 
receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent 
plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is 
registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.
Findings Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible 
to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. 
There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the 
convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 
95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, 
including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent 
plasma had no significant effect on the proportion of patients discharged from hospital within 28 days 
(3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 
95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no 
significant difference in the proportion of patients meeting the composite endpoint of progression to invasive 
mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 
5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79).
Interpretation In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or 
other prespecified clinical outcomes.
Funding UK Research and Innovation (Medical Research Council) and National Institute of Health Research.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
A substantial proportion of individuals with SARS-CoV-2 
require hospital care, which can progress to critical illness 
with hypoxic respiratory failure. In patients with severe 
COVID-19, immunomodulation with corticosteroids and 
IL-6 receptor antagonists has been shown to improve 
survival.1,2 Treatments that effectively inhibit viral replica-
tion might reduce tissue damage and allow time for the 
host to develop an adaptive immune response that can 
clear the infection. However, no treatment directed against 
the virus has been shown to reduce mortality (although 
remdesivir might shorten the duration of hospital stay).3
Humoral immunity is a key component of the immune 
response to SARS-CoV-2, and it matures over several 
weeks following infection. Anti-SARS-CoV-2 antibodies 
are detectable at a mean of 13 days after symptom onset, 
but neutralising titres do not peak until day 23, and there 
is wide variation in both the timing of seroconversion 
and peak antibody concentrations between infected 
individuals.4 Although patients with severe COVID-19 
generally have higher final antibody concentrations than 
those with mild disease, their antibody responses are 
delayed.5 Antibodies might modulate acute viral disease 
either through a direct antiviral effect—by binding and 
neutralising free virus—or indirectly by activating 
antiviral pathways—such as the complement cascade, 
phagocytosis, and cellular cytotoxicity. Conversely, there 
is also a possibility that antibodies might enhance disease, 
either by promoting viral entry or by proinflammatory 
mechanisms, such as Fcγ receptor stimulation.6
Convalescent plasma has been used for more than 
100 years as passive immunotherapy for influenza 
pneumonia, and more recently for SARS-CoV.7 Although 
observational studies have suggested that convalescent 
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plasma might reduce mortality in severe viral respira tory 
infections evidence from randomised trials remains 
scarce and inconclusive.8 Convalescent plasma has been 
used widely outside of clinical trials, including by more 
than 100 000 patients in the US Food and Drugs 
Administration (FDA) Expanded Access Program.9 An 
observational analysis of 3082 patients in this programme 
reported that in patients who had not received mechanical 
ventilation, 30-day mortality was lower in those transfused 
with higher-titre plasma (containing higher concentrations 
of anti-SARS-CoV-2 spike IgG) compared with those who 
received lower-titre plasma.10 A number of randomised 
trials of convalescent plasma in patients hospitalised with 
COVID-19 have been reported, but these trials have all 
been small and inconclusive.11–20 Moreover, patients who 
are hospitalised with COVID-19 are heterogeneous and 
any benefit of convalescent plasma could depend on the 
stage of disease, perhaps being restricted to those with 
milder disease early in the course of their illness or those 
who have not mounted an effective antibody response.14 
Therefore, the efficacy of convalescent plasma as a 
treatment for patients hospitalised with COVID-19 is 
uncertain. We aimed to evaluate the efficacy and safety 
of convalescent plasma in patients hospitalised with 
COVID-19.
Methods
Study design and participants
The RECOVERY trial is an investigator-initiated, indi-
vidually randomised, controlled, open-label, adaptive 
platform trial to evaluate the effects of potential treat ments 
in patients hospitalised with COVID-19. Details of the 
trial design and results for other evaluated treatments 
(dexamethasone, hydroxychloroquine, lopinavir–ritonavir, 
azithromycin, and tocilizumab) have been published 
previously.2 The trial is underway at 177 NHS hospital 
organisations in the UK (appendix pp 5–28), supported by 
the National Institute for Health Research Clinical Research 
Network. The trial was coordinated by the trial sponsor, the 
Nuffield Department of Population Health, University of 
Oxford (Oxford, UK). The trial is being done in accordance 
with the principles of the International Conference on 
Harmonisation–Good Clinical Practice guidelines and 
approved by the UK Medicines and Healthcare products 
Regulatory Agency and the Cambridge East Research 
Ethics Committee (20/EE/0101). The protocol, statistical 
analysis plan, and additional information are available 
online and in the appendix (pp 66–151).
Hospitalised patients of any age were eligible for the 
trial if they had clinically suspected or laboratory-
confirmed SARS-CoV-2 infection and no medical history 
that might, in the opinion of the attending clinician, put 
them at significant risk if they were to participate in the 
trial. Written informed consent was obtained from all 
patients or from their legal representative if they were too 
unwell or unable to provide consent.
Randomisation and masking
Baseline data were collected using a web-based case 
report form that included demographics, level of 
respiratory support, major comorbidities, suitability of 
the trial treatment for a particular patient and treatment 
availability at the trial site (appendix pp 35–37). Patients 
had a serum sample taken before random assignment 
for the purpose of assessing the presence of antibodies 
against SARS-CoV-2.
Research in context
Evidence before this study
We searched the MEDLINE, Embase, MedRxiv, and bioRxiv 
databases from Sept 1, 2019, to March 23, 2021, for randomised 
trials or meta-analyses of trials evaluating the effect of 
convalescent plasma in patients hospitalised with COVID-19 
using the search terms (“COVID-19”, “COVID”, “SARS-CoV-2”, 
“2019-nCoV”, or “Coronavirus”) and (“convalescent plasma” , 
“hyperimmune plasma”, “immune plasma”, “passive 
immunization”, or “plasma therapy”). 12 trials were identified. 
Two trials were excluded from the meta-analysis: one trial of 
49 patients that did not have robust allocation concealment and 
one trial of 30 patients that did not report mortality. In two trials 
participants and clinicians were masked to treatment allocation 
and the remaining eight trials were open-label. There was some 
concern about missing outcome data in one trial, but the 
remaining nine studies were assessed as having a low risk of bias 
when using an outcome of mortality. These trials included 
1495 randomly assigned patients, of whom 218 died. Most of 
these studies recruited patients shortly after admission to 
hospital, as was the case in RECOVERY.
Added value of this study
RECOVERY is the largest randomised trial to report results of 
the effect of convalescent plasma in patients hospitalised with 
COVID-19. We found that compared with usual care alone, 
high-titre convalescent plasma did not reduce 28-day 
mortality, the probability of discharge within 28 days, or the 
probability of progressing to the composite outcome of 
invasive mechanical ventilation or death in patients who were 
not receiving invasive mechanical ventilation at randomisation. 
We saw no evidence of any material benefit or hazard of 
convalescent plasma in any patient subgroup. Taking the results 
of all trials together, including RECOVERY which includes about 
eight-times as much information as all other trials combined, 
allocation to convalescent plasma was associated with a 
mortality rate ratio 0·98 (95% CI 0·91–1·06; p=0·63).
Implications of all the available evidence
For patients admitted to hospital with COVID-19, 
convalescent plasma offers no material therapeutic benefits.
For the protocol, statistical 
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Until Sept 18, 2020, eligible and consenting patients 
were randomly assigned (1:1) to receive either usual care 
(usual care group) or usual care plus convalescent plasma 
(conva lescent plasma group). From Sept 18, 2020, patients 
were randomly assigned (1:1:1) to the usual care group, 
convalescent plasma group, or to receive usual care 
plus REGN-COV2 (a combination of two monoclonal 
antibodies directed against SARS-CoV-2 spike protein; 
appendix pp 35–37). The REGN-COV2 evaluation is 
ongoing and not reported here. Random assignment was 
unstratified and done by local clinical or research staff 
using a web-based interface with allocation concealment 
(appendix pp 33–34). For some patients, convalescent 
plasma was either declined, unavailable at the trial site at 
the time of enrolment, or considered in the opinion of the 
attending doctor to be definitely contraindicated (eg, 
known moderate or severe allergy to blood components). 
These patients were not included in the comparison of 
convalescent plasma versus usual care.
In a factorial design, patients could be simultaneously 
randomly assigned to other treatment groups: (1) hydroxy-
chloroquine or dexamethasone or azithromycin or 
lopinavir–ritonavir or colchicine versus usual care, and 
(2) aspirin versus usual care (appendix pp 33–34). The 
trial also allowed a subsequent randomisation for patients 
with progressive COVID-19 (evidence of hypoxia and a 
hyperinflammatory state) to tocilizumab versus usual 
care. Participants and local study staff were not masked 
to the allocated treatment. Several of these treatment 
groups were added to or removed from the protocol 
over the period that convalescent plasma was evaluated 
(appendix pp 29–34). The trial steering committee, 
investigators, and all other indi viduals involved in the 
trial were masked to outcome data during the trial.
Procedures
Convalescent plasma donors were recruited and screened 
by the four UK blood services: NHS Blood and Transplant, 
the Northern Ireland Blood Transfusion Service, the 
Scottish National Blood Transfusion Service, and the 
Welsh Blood Service (appendix pp 2–4, 29). Only plasma 
donations with a sample to cutoff ratio of 6·0 or more 
on the EUROIMMUN IgG enzyme-linked immuno-
sorbent assay (ELISA) targeting the spike glycoprotein 
(PerkinElmer, London, UK) were supplied for the 
RECOVERY trial (appendix p 29). EUROIMMUN IgG 
has been shown to correlate well with neutralisation 
assays, and a sample to cutoff ratio of 6·0 or more was 
previously shown to be associated with neutralising titres 
of 1:100 or more in convalescent plasma.21–24 The US FDA 
has determined that convalescent plasma with a 
EUROIMMUN sample to cutoff of 3·5 or more qualifies 
as high titre and can be used for the treatment of 
hospitalised patients under an Emergency Use Authorisa-
tion.9 Patients in the convalescent plasma group received 
two units (275 ml [200–350]) intra venously, the first as 
soon as possible after randomisation and the second 
(from a different donor) the following day and at least 12 h 
after the first.
Early safety outcomes were recorded by site staff using an 
online form 72 h after randomisation (appendix pp 38–42). 
An online follow-up form was completed by site staff 
when patients were discharged, had died, or at 28 days 
after ran domisation, whichever occurred first (appendix 
pp 43–49). Informa tion was recorded on adherence to 
allocated trial treat ment, receipt of other COVID-19 
treatments, duration of admission, receipt of respiratory or 
renal support, and vital status (including cause of death). 
In addition, routine health-care and registry data were 
obtained, including information on vital status at day 28 
(with date and cause of death); discharge from hospital; and 
receipt of respiratory support or renal replacement therapy.
Baseline SARS-CoV-2 serostatus for each participant 
was determined using serum samples taken at the time 
of randomisation. Analysis was done at a central 
laboratory with a validated 384 well plate indirect ELISA 
(appendix p 29).25 Participants were categorised as 
seropositive or seronegative using a predefined assay 
threshold with a 99% or higher sensitivity and specificity 
in detecting individuals with SARS-CoV-2 infection at 
least 20 days previously.25
Outcomes
Outcomes were assessed at 28 days after randomisation, 
with additional analyses specified at 6 months. The 
primary outcome was all-cause mortality. Secondary 
outcomes were time to discharge from hospital and, 
in patients not receiving mechanical ventilation at 
random isa tion, subsequent receipt of invasive mecha-
nical ventilation (including extra-corporeal membrane 
oxygenation) or death. Prespecified, sub sidiary clinical 
outcomes included receipt of ventila tion, time to 
successful cessation of invasive mechanical ventilation 
(defined as removal of invasive mechanical ventilation 
within, and survival to, 28 days), and use of renal dialysis 
or haemofiltration.
Prespecified safety outcomes were transfusion related 
adverse events at 72 h following randomisation 
(worsening respiratory status, suspected transfusion 
reaction, fever, hypotension, haemolysis, and thrombotic 
events), cause-specific mortality, and major cardiac 
arrhythmia. Information on serious adverse reactions 
to convalescent plasma was collected in an expedited 
fashion via the existing NHS Serious Hazards of 
Tranfusion haemovigilence scheme.
Statistical analysis
In accordance with the statistical analysis plan, an 
intention-to-treat comparison was done between patients 
in the convalescent plasma group and those in the usual 
care group for whom convalescent plasma was both 
available and suitable as a treatment. For the primary 
outcome of 28-day mortality, the log-rank observed minus 
expected statistic and its variance were used both to test 
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the null hypothesis of equal survival curves (ie, the log-
rank test) and to calculate the one-step estimate of 
the average mortality rate ratio. We used Kaplan-Meier 
survival curves to display cumulative mortality over the 
28-day period. We used similar methods to analyse time to 
hospital discharge and successful cessation of invasive 
mechanical ventilation, with patients who died in hospital 
right-censored on day 29. Median time to discharge was 
derived from Kaplan-Meier estimates. For the prespecified, 
composite, secondary outcome of progression to invasive 
mechanical ventilation or death within 28 days (in those 
not receiving invasive mechanical ventilation at ran-
domisation) and the subsidiary clinical outcomes of 
receipt of ventilation and use of haemo dialysis or 
haemofiltration, the precise dates were not available so the 
risk ratio was estimated instead.
Prespecified analyses of the primary outcome were 
done in seven subgroups defined by characteristics at 
randomisation: age, sex, ethnicity, respiratory support 
received, days since symptom onset, use of systemic 
corticosteroids, and presence of anti-SARS-CoV-2 
anti body. Observed effects within these subgroup 
categories were compared using a χ² test. Subgroup 
analyses according to these baseline characteristics 
were also done for the secondary outcomes. Post-hoc 
exploratory analyses of the primary outcome included 
examination by days since symptom onset, using four 
subcategories rather than the two that were prespecified, 
and level of respiratory support by subdividing the 
oxygen only group into three subcategories. In late 
2020, a new SARS-CoV-2 variant, named B.1.1.7, with 
multiple substitutions in the receptor binding domain 
of the spike glycoprotein emerged in southeast England 
and rapidly grew to become the dominant virus variant 
throughout the UK.26 Conva lescent plasma from 
individuals infected before the emergence of B.1.1.7 
show a modest reduction in ability to neutralise B.1.1.7 
compared with earlier SARS-CoV-2 virus variants.27 
The clinical significance of this reduced in-vitro 
neutralisation is not known. To assess if there was 
evidence of a difference in the effectiveness of con-
valescent plasma before and after the emergence 
of B.1.1.7, an additional post-hoc exploratory analysis 
was done of the primary outcome comparing effects in 
patients randomly assigned before Dec 1, 2020, with 
those randomly assigned from Dec 1, 2020, onwards.26
Additional sensitivity analyses included restricting 
analysis of the primary outcome to patients with a posi-
tive PCR test for SARS-COV-2 and repeating subgroup 
analyses of the primary and secondary outcomes by 
presence of anti-SARS-CoV-2 antibody after adjustment 
for age. Age adjustment was done because in seronegative 
patients those assigned to the convalescent plasma group 
were slightly younger than those assigned to the usual 
care group, whereas in seropositive patients those 
assigned to the convalescent plasma group were slightly 
older than those assigned to the usual care group. A 
final prespecified exploratory analysis estimated whether 
the effect of allocation to convalescent plasma varied 
depending on whether the patient was simul taneously 
allocated azithromycin (the only other treatment that has 
both already reported its results and to which substantial 
numbers of patients could have been assigned at the 
same time as they were randomly assigned to receive 
convalescent plasma or usual care).
Estimates of rate and risk ratios are shown with 
95% CIs. All p values are two-sided and are shown 
without adjustment for multiple testing. The full 
database is held by the trial team who pooled the data 
from trial sites and did the analyses at the Nuffield 
Department of Population Health, University of Oxford.
For the primary outcome of 28-day mortality, the 
results from RECOVERY were subsequently included in 
a meta-analysis of results from all previous randomised 
trials of convalescent plasma versus usual care in 
patients with COVID-19. For each trial, we compared the 
observed number of deaths among patients allocated 
convalescent plasma with the expected number if all 
Figure 1: Trial profile
*Number recruited overall during period that patients could be recruited into convalescent plasma comparison. 
†Reasons for exclusion are not mutually exclusive. ‡Patients in the group are not included in the analyses of this 
study. §5301 of 5795 patients with completed follow-up at time of analysis received convalescent plasma. ¶17 of 
5763 patients with completed follow-up at time of analysis received convalescent plasma. ||A second 
randomisation to tocilizumab versus usual care in patients with hypoxia and C-reactive protein ≥75 mg/L was 
introduced in protocol version 4.0; 426 patients in the convalescent plasma group were randomly assigned to 
receive tocilizumab with 486 randomly assigned to receive usual care alone; 573 patients in the usual care group 
were randomly assigned to receive tocilizumab with 552 randomly assigned to receive usual care alone.
5795 allocated convalescent plasma§ 
23 withdrew consent
13 127 eligible for randomisation 
to convalescent plasma
11 558 randomised between 
convalescent plasma and 
usual care
16 287 patients recruited*
912 included in second randomisation||
16 withdrew consent
1125 included in second randomisation||
5763 allocated usual care¶
5795 included in 28-day 
intention-to-treat analysis
5763 included in 28-day 
intention-to-treat analysis
1569 allocated REGN-COV-2‡ 
3160 excluded† 
965 convalescent plasma unavailable
2764 unsuitable for convalescent plasma
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patients were at equal risk (ie, we calculated the observed 
minus expected statistic [o–e], and its variance [v]). For 
RECOVERY, these were taken as the log-rank observed 
minus expected statistic and its variance but for other 
trials, where the exact timing of each death was not 
available, these were calculated from standard formulae 
for 2 × 2 contingency tables. We then combined trial 
results using the log of the mortality rate ratio calculated 
as the inverse-variance weighted average S/V with 
variance 1/V (and hence with 95% CI S/V ±1·96/√V), 
where S is the sum over all trials of (O–E) and V is the 
sum over all trials of v. Analyses were done with SAS 
(version 9.4) and R (version 3.4).
As stated in the protocol, appropriate sample sizes 
could not be estimated when the trial was being planned 
at the start of the COVID-19 pandemic. During the 
trial, external data suggested that any benefits of 
antibody-based therapies might be higher in patients who 
had not raised an adequate antibody response of their 
own.14 Consequently, while still masked to the results of 
the trial, the RECOVERY steering committee determined 
that the trial should enrol sufficient patients to provide at 
least 90% power at a two-sided p value of 0·01 to detect 
a proportional reduction in 28-day mortality of a fifth 
in patients with and, separately, without detectable 
SARS-CoV-2 antibodies at ran domisation (appendix p 34).
On Jan 7, 2021, the independent data monitoring 
committee did a routine review of the data and 
recommended that the chief investigators pause 
recruitment to the convalescent plasma comparison in 
those patients receiving invasive mechanical ventilation 
(including extracorporeal membrane oxygenation) at the 
time of randomisation. At the same time, the committee 
recommended that recruitment to the convalescent 
plasma comparison continue for all other eligible patients.
On Jan 14, 2021, the data monitoring committee did 
another routine review of the data and notified the chief 
investigators that there was no convincing evidence that 
continued recruitment would provide conclusive proof 
of worthwhile mortality benefit, either overall or in any 
prespecified subgroup. The committee recommended 
that recruitment to the convalescent plasma portion of 
the study should cease and follow-up be completed. 
Enrolment of patients to the convalescent plasma 
comparison was closed on Jan 15, 2021, and the 
preliminary result for the primary outcome was made 




Usual care group 
(n=5763)
Mean age, years 63·5 (14·7) 63·4 (14·6)
Age groups
<70* 3705 (64%) 3748 (65%)
70–79 1310 (23%) 1281 (22%)
≥80 780 (13%) 734 (13%)
Sex
Men 3643 (63%) 3787 (66%)
Women† 2152 (37%) 1976 (34%)
Ethnicity
White 4493 (78%) 4421 (77%)
Black, Asian, and minority 
ethnic
833 (14%) 887 (15%)
Unknown 469 (8%) 455 (8%)
Median number of days since 
symptom onset
9 (6–12) 9 (6–12)
Median number of days since 
admission to hospital
2 (1–3) 2 (1–4)
Respiratory support received
No oxygen received 442 (8%) 455 (8%)
Oxygen only‡ 5051 (87%) 4993 (87%)
Invasive mechanical 
ventilation
302 (5%) 315 (5%)
Previous diseases
Diabetes 1535 (26%) 1569 (27%)
Heart disease 1267 (22%) 1309 (23%)
Chronic lung disease 1385 (24%) 1328 (23%)
Tuberculosis 20 (<1%) 23 (<1%)
HIV 17 (<1%) 19 (<1%)
Severe liver disease§ 70 (1%) 72 (1%)
Severe kidney impairment¶ 323 (6%) 293 (5%)
Any of the above 3203 (55%) 3222 (56%)
(Table 1 continues in next column)
Convalescent plasma 
group (n=5795)
Usual care group 
(n=5763)
(Continued from previous column)
SARS-CoV-2 PCR test result
Positive 5593 (97%) 5566 (97%)
Negative 126 (2%) 116 (2%)
Unknown 76 (1%) 81 (1%)
Patient SARS-CoV-2 antibody test result
Positive 3078 (53%) 2810 (49%)
Negative 2016 (35%) 1660 (29%)
Missing 701 (12%) 1293 (22%)
Corticosteroids received
Yes 5370 (93%) 5311 (92%)
No 391 (7%) 413 (7%)
Not recorded 34 (1%) 39 (1%)
Other randomised treatments
Lopinavir–ritonavir 5 (<1%) 14 (<1%)
Dexamethasone 3 (<1%) 3 (<1%)
Hydroxychloroquine 1 (<1%) 0
Azithromycin 587 (10%) 585 (10%)
Colchicine 792 (14%) 791 (14%)
Aspirin 1266 (22%) 1207 (21%)
Data are mean (SD), n (%), or median (IQR). *Includes 26 children (<18 years). 
†Includes 28 pregnant women. ‡Includes non-invasive ventilation. §Defined as 
requiring ongoing specialist care. ¶Defined as estimated glomerular filtration rate 
<30 mL/min per 1·73 m².
Table 1: Baseline characteristics
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Role of the funding source
The funders of the trial had no role in trial design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
Between May 28, 2020, and Jan 15, 2021, 13127 (81%) of 
16 287 patients enrolled into the RECOVERY trial were 
eligible to receive convalescent plasma (figure 1). 
1569 (12%) were randomly assigned to the REGN-COV-2 
group and are not included in the analyses reported 
here. Of the remaining 11558 patients, 5795 (50%) were 
randomly assigned to the convalescent plasma 
group and 5763 (50%) to the usual care group. The 
mean age of the patients was 63·5 (SD 14·7) years, 
and the median time from symptom onset to ran-
domisation was 9 days (IQR 6–12; table 1; appendix 
p 51). At randomisation, 617 (5%) of 11 558 patients 
were receiving invasive mechanical ventilation, 
10 044 (87%) were receiving oxygen only (with or 
without non-invasive respiratory support), and 897 (8%) 
were receiving no oxygen therapy (appendix p 51). 
10 681 (92%) of 11 558 patients were receiving cortico-
steroids at time of randomisation. By chance, a slightly 
lower proportion of men were randomly assigned to the 
convalescent plasma group than the usual care group, 






































Figure 3: Effect of allocation to convalescent plasma on 28-day mortality by prespecified characteristics at randomisation
The ethnicity, days since onset, and use of corticosteroids subgroups exclude those with missing data, but these patients are included in the overall summary. 
Information on use of corticosteroids was collected from June 18, 2020, onwards following announcement of the results of the dexamethasone comparison from the 
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(appendix p 57), which are almost identical to the main 
results shown.
Baseline serology result were available for 9564 (83%) 
of 11 558 patients, of whom 3676 (38%) were SARS-CoV-2 
antibody seronegative (appendix p 51). Patients were 
more likely to be sero negative if they were older, female, 
White, had shorter duration of symptoms, were receiving 
less intensive respiratory support, or were SARS-CoV-2 
RNA negative by PCR (appendix p 52). There was an 
imbalance in the availability of a baseline serology 
sample, with more missing samples in the usual care 
group (table 1).
In the convalescent plasma group, 4657 (80%) of 
5795 patients received two units, 644 (11%) received one 
unit, and 494 (9%) received no units (appendix p 53). 
Two (<1%) patients received both convalescent plasma 
units from the same donor. In the usual care group, 
17 (<1%) of 5763 patients received convalescent plasma. 
For patients in whom the time of issue of convalescent 
plasma by the transfusion laboratory was known, 
5030 (96%) of 5217 patients had their first unit of 
plasma issued within 36 h of randomisation. Use of 
corticosteroids and remdesivir following randomisa tion 
was similar between the two groups (appendix p 53). 
Slightly fewer patients received tocilizumab or sarilumab 
in the convalescent plasma group (447 [8%] of 5795) than 
in the usual care group (589 [10%] of 5763 patients; 
appendix p 53).
Primary and secondary outcome data were known for 
99% of randomly assigned patients. There was no 
significant difference in 28-day mortality between the 
two groups: 1399 (24%) of 5795 patients died in 
the convalescent plasma group and 1408 (24%) of 
5763 patients died in the usual care group (rate ratio 1·00, 
95% CI 0·93–1·07; p=0·95; figure 2). We observed 
similar results across all subgroups with no good 
evidence of heterogeneity of effect in either the 
prespecified (figure 3) or the exploratory post-hoc 
(appendix p 59) subgroup analyses (all p values 
were >0·05). Results were similar in analyses restricted 
to patients with a positive SARS-CoV-2 test (rate ratio 1·00, 
95% CI 0·93–1·08; p=0·93) and there was no evidence 
that the rate ratio differed depending on allocation to 
azithromycin (p>0·1). Although 28-day mortality was 
higher in patients who were seronegative at ran-
domisation, the proportional effect of allocation to 
convalescent plasma on 28-day mortality was similar in 
seropositive patients (575 [19%] of 3078 patients in the 
convalescent plasma group vs 501 [18%] of 2810 patients 
in the usual care group; rate ratio 1·06, 95% CI 0·94–1·19) 
and seronegative patients (642 [32%] of 2016 patients 
in the convalescent plasma group vs 558 [34%] of 
1660 patients in the usual care group; rate ratio 0·96, 
95% CI 0·85–1·07; figure 3; appendix p 60). In ten 
other reported randomised trials, including a total of 
1495 patients hospitalised with COVID-19, 218 of 
whom died, convalescent plasma was associated with a 
non-significant reduction in mortality (rate ratio 0·77, 
95% CI 0·57–1·04; p=0·08; figure 4).11–20 After inclusion 
of the results from RECOVERY (which includes nearly 
eight-times as many patients and more than 11-times 
as many events as the other trials combined) into this 
Figure 4: Meta−analysis of mortality in RECOVERY and other trials
O–E=observed–expected. Var=variance. RR=rate ratio.*Log−rank O−E for RECOVERY, O−E from 2 × 2 contingency tables for the other trials. RR is calculated by taking 
ln rate ratio to be (O−E)/V with normal variance 1/V, where V=Var (O–E). Subtotals or totals of (O−E) and of V yield inverse-variance weighted averages of the ln rate 
ratio values. †For balance, controls in the 2:1 studies count twice in the control totals and subtotals, but do not count twice when calculating their O−E or V values. 
Heterogeneity between RECOVERY and ten previous trials combined, χ₁²=2·7 (p=0·10).
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meta-analysis, the mortality rate ratio was 0·98 (95% CI 
0·91–1·06; p=0·63; figure 4).
The median time to discharge was 12 days in the 
convalescent plasma group and 11 days in the usual care 
group (IQR 6 to >28 in both groups); patients in the 
convalescent plasma group had a similar probability of 
being discharge alive within 28 days compared with the 
usual care group (3832 [66%] of 5795 patients in the 
convalescent plasma group vs 3822 [66%] of 5763 patients 
in the usual care group; rate ratio 0·99, 95% CI 
0·94 to 1·03; p=0·57; table 2). Of the patients who were 
not receiving invasive mechanical ventilation at baseline, 
the number of patients progressing to the prespecified 
composite secondary outcome of invasive mechanical 
ventilation or death was similar in the two groups 
(1568 [29%] of 5493 patients in the convalescent plasma 
group vs 1568 [29%] of 5448 patients in the usual care 
group; rate ratio 0·99, 95% CI 0·93 to 1·05; p=0·79; 
table 2). For both of these secondary outcomes, there was 
some evidence of heterogeneity by patient SARS-CoV-2 
antibody test result, with slightly more favourable 
outcomes with convalescent plasma in patients who were 
seronegative at baseline compared with those who were 
seropositive (appendix pp 61–62). Because of slight 
age-imbalances between treatment groups for both 
seropositive and seronegative patients, an exploratory 
analysis was done that included adjust ment for age, 
which marginally reduced the apparent heterogeneity 
(heterogeneity p=0·02 for both secondary outcomes after 
age adjustment). Results were consistent across all other 
prespecified subgroups of patients.
There were no significant differences in the prespeci-
fied subsidiary clinical outcomes of use of ventilation, 
successful cessation of invasive mechanical ventilation, 
or progression to use of renal replacement therapy 
(table 2), or in cause-specific mortality (appendix p 54).
Within the first 72 h after randomisation, severe allergic 
reactions were reported in 16 (<1%) of 5795 patients in 
the convalescent plasma group and two (<1%) of 
5763 patients in the usual care group. The frequency of 
sudden worsening in respiratory status, temperature 
higher than 39°C or a 2°C or higher increase in tem-
perature above baseline, sudden hypotension, clinical 
haemolysis, and thrombotic events were broadly similar 
in the two groups (appendix p 55). We also observed 
no significant differences in the frequency of major 
cardiac arrhythmia (appendix p 56). 13 patients receiving 
convalescent plasma had reports submitted to the 
Serious Hazards of Transfusion haemovigilence scheme: 
nine patients with pulmonary reactions (none considered 
to be transfusion-related acute lung injury, including 
three deaths possibly related to transfusion), and four 
patients with serious febrile, allergic, or hypotensive 
reactions (all of whom recovered).
Discussion
The results of this large, randomised trial show that 
convalescent plasma did not improve survival or 
other clinical outcomes in patients hospitalised with 
COVID-19. The results were consistent across sub-
groups of age, sex, ethnicity, duration of symptoms 
before randomisation, level of respiratory support 
received at randomisation, and use of corticosteroids. 
The results are consistent with the evidence from 
previously reported randomised trials of convalescent 
plasma for patients hospitalised with COVID-19,11–20 
with no evidence of a survival benefit when these results 
are combined (figure 4).
It has been suggested that the benefits of convalescent 
plasma depend on the transfused neutralising titre, and 
that using plasma with lower titres could explain negative 
results from previous randomised trials. In RECOVERY, 
all convalescent plasma was supplied via the UK National 
Blood Services using standardised laboratory processing. 
Convalescent donors were chosen based on high anti-spike 
IgG concentrations, using an ELISA that has been shown 
to correlate well with neutralising antibody.22–24 We used a 
EUROIMMUN sample to cutoff ratio of 6·0 for plasma to 
qualify for use in this trial, which is substantially more 
than the 3·5 cutoff that the US FDA recognises as high 
titre.9 Nearly all participants received plasma from 
two different donors to increase the chance that at least 




Usual care group 
(n=5763)
RR (95% CI) p value
Primary outcome
Mortality at 28 days 1399 (24%) 1408 (24%) 1·00 (0·93 to 1·07) 0·95
Secondary outcomes
Median duration of 
hospitalisation, days
12 (6 to >28) 11 (6 to >28) ·· ··
Discharged from hospital 
within 28 days
3832 (66%) 3822 (66%) 0·99 (0·94 to 1·03) 0·57
Invasive mechanical 
ventilation or death*
1568/5493 (29%) 1568/5448 (29%) 0·99 (0·93 to 1·05) 0·79
Invasive mechanical 
ventilation
678/5493 (12%) 690/5448 (13%) 0·97 (0·88 to 1·08) 0·61
Death 1241/5493 (23%) 1263/5448 (23%) 0·97 (0·91 to 1·04) 0·46
Subsidiary outcomes
Use of ventilation† 885/3564 (25%) 876/3441 (25%) 0·98 (0·90 to 1·06) 0·55
Non-invasive ventilation 856/3564 (24%) 845/3441 (25%) 0·98 (0·90 to 1·06) 0·60
Invasive mechanical 
ventilation
229/3564 (6%) 238/3441 (7%) 0·93 (0·78 to 1·11) 0·41
Successful cessation of 
invasive mechanical 
ventilation‡
85/302 (28%) 108/315 (34%) 0·79 (0·59 to 1·05) 0·11
Renal replacement therapy§ 250/5707 (4%) 241/5697 (4%) 1·04 (0·87 to 1·23) 0·69
Data are n (%), median (IQR) or n/N (%). RR=rate ratio for the outcomes of 28-day mortality, hospital discharge, and 
successful cessation of invasive mechanical ventilation, and risk ratio is calculated for all other outcomes. *Analyses 
exclude those on invasive mechanical ventilation at randomisation. †Analyses exclude those on invasive or 
non-invasive ventilation at randomisation. ‡Analyses exclude those not receiving invasive mechanical ventilation at 
randomisation. §Analyses exclude those on renal replacement therapy at randomisation.
Table 2: Primary, secondary, and subsidiary outcomes
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The presence of anti-SARS-CoV-2 antibodies in 
recipients at the time of transfusion with convalescent 
plasma has also been cited as a possible reason for the 
absence of an observed effect.14 In this trial we found that 
38% of patients were seronegative at randomisation, 
and, although they had a markedly higher 28-day 
mortality risk than patients who were seropositive at 
randomisation, we did not observe a significant survival 
benefit from convalescent plasma in these patients. 
Our results do not exclude the possibility of small 
improvements in the probability of successful discharge 
from hospital by day 28 or of progressing to invasive 
mechanical ventilation or death in seronegative patients 
who received convalescent plasma. However, the results 
of these secondary outcomes in one subgroup should be 
interpreted with caution given the multiple testing; 
additionally, when an age-adjusted analysis was done the 
apparent heterogeneity was slightly reduced.
It has also been suggested that antibody-based therapies 
could be most effective in the early stages of COVID-19, 
when viral replication dominates.10,28 We did not identify 
a benefit of convalescent plasma when patients were 
stratified by time since onset of illness in the main 
analysis or in an exploratory analysis, which subdivided 
participants on the basis of illness onset. Of note, we did 
not identify a mortality benefit in the subgroup of patients 
allocated to convalescent plasma 4 days or less from illness 
onset, which by itself comprised more patients than the 
total number of patients enrolled in all other convalescent 
plasma trials combined. However, RECOVERY only 
included patients admitted to hospital; therefore, the trial 
does not address whether convalescent plasma has any 
benefit if given early after SARS-CoV-2 infection and 
before the onset of significant disease. That question 
has not yet been robustly tested in sufficiently large 
randomised controlled trials.28
Following random assignment to receive convalescent 
plasma, patients with hypoxia and a raised C-reactive 
protein (≥75mg/L) were eligible for a second random 
assignment to receive usual care or usual care plus 
tocilizumab. Although a slightly lower proportion of 
patients allocated convalescent plasma (8%) subsequently 
received tocilizumab than patients allocated usual care 
(10%; appendix p 53), and although tocilizumab itself 
reduces 28-day mortality by around 15%,1 this dif -
ference is far too small to have had any material effect on 
our estimate of the effect of convalescent plasma on 
mortality (estimated 0·1% difference in 28 day mortality).
SARS-CoV-2 is an RNA virus with antigenic variability. 
The efficacy of convalescent plasma is likely to depend on 
the match between the strain-specific transfused anti-
SARS-CoV-2 antibodies in donor plasma and the infecting 
virus variant in the recipient. In December, 2020, a new 
SARS-CoV-2 variant (B.1.1.7) was detected in the southeast 
and east of England, with an earliest date of detection in 
September, 2020. B.1.1.7 spread rapidly to become the 
dominant SARS-CoV-2 variant, in most regions of the UK, 
by January, 2021.29 Although B.1.1.7 has changes in 
the spike glycoprotein that could theoretically modify 
antigenicity, only modest reductions in neutralisation by 
convalescent plasma have been reported.27 Consistent 
with this, we did not identify any evidence of a diff erential 
effect of convalescent plasma before and after the 
emergence of B.1.1.7 in the UK (appendix p 59).
During an epidemic caused by a novel virus, convalescent 
plasma is an appealing treatment because it might be 
available within weeks of the outbreak, long before other 
targeted therapies are available. Consequently, convalescent 
plasma has been widely used for COVID-19 outside of 
clinical trials but, until now, there has been insufficient 
evidence from randomised trials to reliably assess its safety 
and efficacy.10 In RECOVERY, the largest clinical trial of 
convalescent plasma for any infectious indication, we did 
not find evidence that high-titre convalescent plasma 
improved survival or other prespecified clinical outcomes 
in patients hospitalised with COVID-19. Whether conva-
lescent plasma would benefit other patient groups is 
unknown and would need to be evaluated in other, 
adequately powered, randomised clinical trials.
Contributors
This manuscript was initially drafted by the PWH and MJL, further 
developed by the Writing Committee, and approved by all members of 
the trial steering committee. PWH and MJL vouch for the data and 
analyses, and for the fidelity of this report to the trial protocol and data 
analysis plan. PWH, LE, LP, MM, JKB, LCC, SNF, TJ, KJ, WSL, AM, KR, 
EJ, DJR, RH, and MJL designed the trial and trial protocol. MM, AR, 
GP-A, NJB, TG, DZ, ST, NNA, AU, JW, GK, TB, SS, RH, the Data 
Linkage team at the RECOVERY Coordinating Centre, and the health 
records and local clinical centre staff listed in the appendix collected the 
data. ES, NS, and JRE did the statistical analysis. LE, DJR, and the blood 
and transfusion service staff listed in the appendix coordinated the 
collection and supply of convalescent plasma. All authors contributed to 
data interpretation and critical review and revision of the manuscript. 
PWH and MJL had access to the trial data and had final responsibility for 
the decision to submit for publication.
Writing Committee (on behalf of the RECOVERY Collaborative Group)
Peter W Horby, Lise Estcourt, Leon Peto, Jonathan R Emberson, 
Natalie Staplin, Enti Spata, Guilherme Pessoa-Amorim, Mark Cambell, 
Alistair Roddick, Nigel J Brunskill, Tina George, Daniel Zehnder, 
Simon Tiberi, Ni Ni Aung, Alison Uriel, John Widdrington, George Koshy, 
Thomas Brown, Stephen Scott, J Kenneth Baillie, Maya H Buch, 
Lucy C Chappell, Jeremy N Day, Saul N Faust, Thomas Jaki, Katie Jeffery, 
Edmund Juszczak, Wei Shen Lim, Marion Mafham, Alan Montgomery, 
Andrew D Mumford, Kathryn Rowan, Guy Thwaites, David J Roberts, 
Richard Haynes, Martin J Landray. PWH, LE, and LP contributed equally, 
and DJR, RH, and MJL contributed equally.
Data Monitoring Committee
Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, 
David Lalloo, Ian Roberts (until December 2020), Mohammed Munavvar 
(from January 2021), Janet Wittes.
Declaration of interests
We declare no competing interests.
Data sharing
The protocol, consent form, statistical analysis plan, definition and 
derivation of clinical characteristics and outcomes, training materials, 
regulatory documents, and other relevant trial materials are available 
online. As described in the protocol, the trial steering committee will 
facilitate the use of the trial data and approval will not be unreasonably 
withheld. Deidentified participant data will be made available to bona 
fide researchers registered with an appropriate institution within 
Articles
10 www.thelancet.com   Published online May 14, 2021   https://doi.org/10.1016/S0140-6736(21)00897-7
3 months of publication. However, the steering committee will need to 
be satisfied that any proposed publication is of high quality, honours the 
commitments made to the trial patients in the consent documentation 
and ethical approvals, and is compliant with relevant legal and regulatory 
requirements (eg, relating to data protection and privacy). The steering 
committee will have the right to review and comment on any draft 
manuscripts before publication. Data will be made available in line with 
the policy and procedures available online. Those wishing to request 
access should complete the form available online and emailed to data.
access@ndph.ox.ac.uk.
Acknowledgments
We would like to thank the thousands of patients who participated in 
this trial. We would also like to thank the many doctors, nurses, 
pharmacists, other allied health professionals, and research 
administrators at 177 NHS hospital organisations across the whole of the 
UK, supported by staff at the National Institute of Health Research 
(NIHR) Clinical Research Network, NHS DigiTrials, NHS Blood and 
Transplant, the Scottish National Blood Transfusion Service, the Welsh 
Blood Service, the Northern Ireland Blood Transfusion Service, Public 
Health England, Department of Health & Social Care, the Intensive Care 
National Audit & Research Centre, Public Health Scotland, National 
Records Service of Scotland, the Secure Anonymised Information 
Linkage at University of Swansea, Swansea, UK, and the NHS in 
England, Scotland, Wales and Northern Ireland. The RECOVERY trial is 
supported by a grant to the University of Oxford from UK Research and 
Innovation (UKRI) and NIHR (MC_PC_19056), by the Department of 
Health and Social Care (DHSC), UKRI, and NIHR COVID-19 Rapid 
Response Grant (COV19-RECPLA), and by core funding provided by 
NIHR Oxford Biomedical Research Centre, the Wellcome Trust, 
the Bill & Melinda Gates Foundation, the Department for International 
Development, Health Data Research UK, the Medical Research Council 
Population Health Research Unit, the NIHR Health Protection Unit in 
Emerging and Zoonotic Infections, NHS Blood and Transplant Research 
and Development Funding, EU’s Horizon 2020 research and innovation 
programme (SUPPORT-E - 101015756), and NIHR Clinical Trials Unit 
Support Funding. TJ is supported by a grant from UK Medical Research 
Council (MC_UU_0002/14) and an NIHR Senior Research Fellowship 
(NIHR-SRF-2015-08-001). WSL is supported by core funding provided by 
NIHR Nottingham Biomedical Research Centre. AbbVie contributed 
some supplies of lopinavir–ritonavir for use in this trial. Tocilizumab 
was provided free of charge for this trial by Roche. REGN-COV2 was 
provided free of charge for this trial by Regeneron. The collection of 
plasma was funded by the DHSC through core funding and funding 
under COVID-19 and EU SoHo Grant. The views expressed in this 
publication are those of the authors and not necessarily those of the 
NHS, the NIHR, NHS Blood and Transplant, the DHSC, or the EU.
References
1 RECOVERY Collaborative Group. Tocilizumab in patients 
admitted to hospital with COVID-19 (RECOVERY): a randomised, 
controlled, open-label, platform trial. Lancet 2021; 397: 1637–45.
2 RECOVERY Collaborative Group, Horby P, Lim WS, et al. 
Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 
2021; 384: 693–704.
3 Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the 
treatment of Covid-19—final report. N Engl J Med 2020; 
383: 1813–26.
4 Seow J, Graham C, Merrick B, et al. Longitudinal observation and 
decline of neutralizing antibody responses in the three months 
following SARS-CoV-2 infection in humans. Nat Microbiol 2020; 
5: 1598–607.
5 Li K, Huang B, Wu M, et al. Dynamic changes in anti-SARS-CoV-2 
antibodies during SARS-CoV-2 infection and recovery from 
COVID-19. Nat Commun 2020; 11: 6044.
6 Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent 
enhancement and SARS-CoV-2 vaccines and therapies. 
Nat Microbiol 2020; 5: 1185–91.
7 Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. 
The effectiveness of convalescent plasma and hyperimmune 
immunoglobulin for the treatment of severe acute respiratory 
infections of viral etiology: a systematic review and exploratory 
meta-analysis. J Infect Dis 2015; 11: 80–90.
8 Devasenapathy N, Ye Z, Loeb M, et al. Efficacy and safety of 
convalescent plasma for severe COVID-19 based on evidence in 
other severe respiratory viral infections: a systematic review and 
meta-analysis. CMAJ 2020; 192: E745–55.
9 US Department of Health and Human Services Food and Drug 
Administration. Letter of Authorization, Reissuance of Convalescent 
Plasma EUA. 2021. https://www.fda.gov/media/141477/download 
(accessed April 27, 2021).
10 Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent plasma 
antibody levels and the risk of death from Covid-19. N Engl J Med 
2021; 384: 1015–27.
11 Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on 
time to clinical improvement in patients with severe and life-
threatening COVID-19: a randomized clinical trial. JAMA 2020; 
324: 460–70.
12 Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in 
the management of moderate covid-19 in adults in India: open label 
phase II multicentre randomised controlled trial (PLACID Trial). 
BMJ 2020; 371: m3939.
13 Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized 
trial of convalescent plasma in Covid-19 severe pneumonia. 
N Engl J Med 2021; 384: 619–29.
14 Gharbharan A, Jordans CCE, GeurtsvanKessel C, et al. Convalescent 
plasma for COVID-19. A randomized clinical trial. medRxiv 2020; 
published online July 3. https://doi.org/10.1101/2020.07.01.20139857 
(preprint).
15 Bajpai M, Kumar S, Maheshwari A, et al. Efficacy of 
convalescentplasma therapy compared to fresh frozen plasma in 
severely ill COVID-19 patients: a pilot randomized controlled trial. 
medRxiv 2020; published onoine Oct 27. https://doi.org/10.1101/ 
2020.10.25.20219337 (preprint).
16 AlQahtani M, Abdulrahman A, Almadani A, et al. Randomized 
controlled trial of convalescent plasma therapy against standard 
therapy in patients with severe COVID-19 disease. medRxiv 2020; 
published online Nov 4. https://doi.org/10.1101/2020.11.02.20224303 
(preprint).
17 Balcells ME, Rojas L, Le Corre N, et al. Early anti-SARS-CoV-2 
convalescent plasma in patients admitted for COVID-19: 
a randomized phase II clinical trial. PLoS Med 2020; 18: e1003415.
18 Ray Y, Paul SR, Bandopadhyay P, et al. Clinical and immunological 
benefits of convalescent plasma therapy in severe COVID-19: 
insights from a single center open label randomised control trial. 
medRxiv 2020; published online Nov 29. https://doi.org/10.1101/ 
2020.11.25.20237883 (preprint).
19 Avendaño-Solà C, Ramos-Martínez A, Muñez-Rubio E, et al. 
Convalescent Plasma for COVID-19: a multicenter, randomized 
clinical trial. medRxiv 2020; published online Sept 29. https://doi.
org/10.1101/2020.08.26.20182444 (preprint).
20 O’Donnell MR, Grinsztejn B, Cummings MJ, et al. A randomized, 
double-blind, controlled trial of convalescent plasma in adults with 
severe COVID-19. medRxiv 2021; published online March 13. 
https://doi.org/10.1101/2021.03.12.21253373 (preprint).
21 Harvala H, Mehew J, Robb ML, et al. Convalescent plasma 
treatment for SARS-CoV-2 infection: analysis of the first 436 donors 
in England, 22 April to 12 May 2020. Euro Surveill 2020; 25: 2001260.
22 Patel EU, Bloch EM, Clarke W, et al. Comparative performance of 
five commercially available serologic assays to detect antibodies to 
SARS-CoV-2 and identify individuals with high neutralizing titers. 
J Clin Microbiol 2020; 59: e02257-20.
23 Walker GJ, Naing Z, Ospina Stella A, et al. SARS coronavirus-2 
microneutralisation and commercial serological assays correlated 
closely for some but not all enzyme immunoassays. Viruses 2021; 
13: 247.
24 Valdivia A, Torres I, Latorre V, et al. Inference of SARS-CoV-2 
spike-binding neutralizing antibody titers in sera from hospitalized 
COVID-19 patients by using commercial enzyme and 
chemiluminescent immunoassays. Eur J Clin Microbiol Infect Dis 
2021; 40: 485–94.
25 National Sars-CoV-2 Serology Assay Evaluation Group. Performance 
characteristics of five immunoassays for SARS-CoV-2: a head-to-
head benchmark comparison. Lancet Infect Dis 2020; 20: 1390–400.
26 Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility 
and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 2021; 
372: eabg3055.
For data policy and procedures 
see https://www.ndph.ox.ac.uk/
data-access





www.thelancet.com   Published online May 14, 2021   https://doi.org/10.1016/S0140-6736(21)00897-7 11
27 Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of 
SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell 
2021; 184: 2201–21.
28 Libster R, Perez Marc G, Wappner D, et al. Early high-titer plasma 
therapy to prevent severe Covid-19 in older adults. N Engl J Med 
2021; 384: 610–18.
29 Volz E, Mishra S, Chand M, et al. Transmission of SARS-CoV-2 
lineage B.1.1.7 in England: insights from linking epidemiological 
and genetic data. medRxiv 2021; published online Jan 4. https://doi.
org/10.1101/2020.12.30.20249034 (preprint).
